Overview: C4D Immunohistochemistry TestIntroduction: The C4D Immunohistochemistry Test detects complement C4D to diagnose transplant rejection or kidney disorders, causing swelling or pain. Aligned with 2023 ASN guidelines, it uses immunohistochemistry for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected transplant rejection or glomerular diseases.
Other Names: C4D IHC Assay, Transplant Rejection IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: C4D testing for transplant rejection began in the 2000s with kidney transplant research. Immunohistochemistry-based methods improved diagnostic precision for renal pathology.
Purpose: Detects C4D to diagnose transplant rejection or kidney disorders, guides treatment, and evaluates patients with swelling or pain.
Test Parameters: 1. Complement C4D
Pretest Condition: No fasting required. Collect tissue via renal biopsy. Report history of kidney transplant, swelling, or renal dysfunction.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document kidney transplant history, swelling, pain, proteinuria, or renal dysfunction. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, transplant rejection implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect C4D in renal tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for transplant rejection assessment.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive C4D staining suggests antibody-mediated rejection or glomerular disease, guiding immunosuppressive therapy. Negative staining may require further renal testing.
Specialist Consultation: Consult a nephrologist or transplant specialist for result interpretation and treatment planning.
Additional Supporting Tests: HLA antibody testing, renal function tests, or electron microscopy to assess transplant rejection.
Test Limitations: Not specific to one kidney disorder; clinical correlation is needed. Other complement pathways may require testing.
References: ASN Renal Pathology Guidelines, 2023; Kidney International, Colvin RB, 2022.
